Autologous dendritic cell immunotherapy - APAC Biotech

Drug Profile

Autologous dendritic cell immunotherapy - APAC Biotech

Alternative Names: APCEDEN; APCEDEN for RCC; APCEDEN-CR; APCEDEN-L; APCEDEN-O; APCEDEN-P

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator APAC Biotech
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Clinical Phase Unknown Glioblastoma; Renal cell carcinoma

Most Recent Events

  • 13 Apr 2017 Clinical trials in Renal cell carcinoma and Glioblastoma in India (IV) (APAC Biotech's website, April 2017)
  • 05 Apr 2017 Phase-II clinical trials in Solid tumours (Second-line therapy or greater) in India (IV)
  • 05 Apr 2017 Preregistration for Prostate cancer, Ovarian, Colo-rectal and Non Small Cell Lung carcinoma (Second-line therapy or greater) in India (IV) before April 20174
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top